Balázs Hegedűs
YOU?
Author Swipe
View article: Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression
Dual HDAC and PI3K Inhibitor CUDC-907 Inhibits Growth of Pleural Mesothelioma: The Impact of Cisplatin Sensitivity and Myc Expression Open
Objectives: Pleural mesothelioma (PM) is a rare cancer that often develops after a decades-long latency period and confers a grim prognosis. Novel, biomarker-based therapeutic modalities are expected to improve the outcome of patients with…
View article: The prognostic potential of circulating biomarkers for sarcoma patients with pleural dissemination
The prognostic potential of circulating biomarkers for sarcoma patients with pleural dissemination Open
Sarcomas are a heterogeneous group of rare and aggressive malignancies and have a propensity to metastasize to the thoracic cavity. While sarcoma lung metastasectomy is an established modality, only scarce information is available about po…
View article: De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma
De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma Open
Pleural mesothelioma (PM) is one of the deadliest cancers, with limited therapeutic options due to its therapeutically intractable genome, which is characterized by the functional inactivation of tumor suppressor genes (TSGs) and high tumo…
View article: 5% benzoyl peroxide is the most efficient in reducing the cutibacterium flora of the shoulder skin: a network meta-analysis
5% benzoyl peroxide is the most efficient in reducing the cutibacterium flora of the shoulder skin: a network meta-analysis Open
Purpose Our study aims to compare different perioperative treatments to reduce C. acnes , the most common causative agent of surgical site infections following shoulder surgery. Methods A systematic search was performed in MEDLINE (PubMed)…
View article: Characterization of a novel sarcoma cell line with an EWSR1::POU2AF3 fusion
Characterization of a novel sarcoma cell line with an EWSR1::POU2AF3 fusion Open
Sarcomas with an EWSR1::POU2AF3(COLCA2) fusion are a very recently described entity of preferentially sinonasal origin and with undifferentiated round/spindle cell morphology. We established a novel cell line (PF1095) carrying a EWSR1::POU…
View article: NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study Open
Background Immunotherapies targeting the programmed death receptor-1/programmed death ligand-1(PD-1/PD-L1) checkpoint have a major impact on the treatment of both resectable and advanced non-small cell lung cancer (NSCLC). Additional block…
View article: BCL-B Promotes Lung Cancer Invasiveness by Direct Inhibition of BOK
BCL-B Promotes Lung Cancer Invasiveness by Direct Inhibition of BOK Open
Expression of BCL-B, an anti-apoptotic BCL-2 family member, is correlated with worse survival in lung adenocarcinomas. Here, we show that BCL-B can mitigate cell death initiation through interaction with the effector protein BOK. We found …
View article: Diagnostic and prognostic relevance of inflammatory markers in surgically treated thymic epithelial tumors: An international multicenter study
Diagnostic and prognostic relevance of inflammatory markers in surgically treated thymic epithelial tumors: An international multicenter study Open
Using the so-far largest cohort of surgically treated TET patients, our study demonstrates that CRP, PLR, and NLR have diagnostic significance in TETs, while elevated PLR and fibrinogen constitute independent negative prognosticators for O…
View article: Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer
Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer Open
Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new …
View article: Bilateral lung volume reduction surgery outperforms the unilateral approach in functional improvement
Bilateral lung volume reduction surgery outperforms the unilateral approach in functional improvement Open
OBJECTIVES Lung volume reduction surgery (LVRS) is an established treatment approach for patients with severe pulmonary emphysema, enhancing lung function and quality of life in selected patients. Functional benefits and outcomes after uni…
View article: Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma
Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma Open
View article: Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial Open
View article: Evolutionary trajectories of small cell lung cancer under therapy
Evolutionary trajectories of small cell lung cancer under therapy Open
View article: Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors Open
View article: Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma Open
This is the first study demonstrating KL-6 as a potential novel liquid-based diagnostic and prognostic biomarker in PM.
View article: Induction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
Induction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma Open
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Currently, multimodality treatment including chemotherapy with cisplatin or carboplatin in combination with pemetrexed offers the best options…
View article: Early Detection of Lung Cancer Using Small RNAs
Early Detection of Lung Cancer Using Small RNAs Open
These data suggest the potential of a small RNA-based blood test as a viable alternative to low-dose computed tomography screening for early detection of smoking-associated lung cancer.
View article: Circulating <scp>FGF18</scp> is decreased in pleural mesothelioma but not correlated with disease prognosis
Circulating <span>FGF18</span> is decreased in pleural mesothelioma but not correlated with disease prognosis Open
Background Pleural mesothelioma (PM) is a relatively rare malignancy with limited treatment options and dismal prognosis. We have previously found elevated FGF18 expression in PM tissue specimens compared with normal mesothelium. The objec…
View article: Laser ablation‐inductively coupled plasma‐mass spectrometry analysis reveals differences in chemotherapeutic drug distribution in surgically resected pleural mesothelioma
Laser ablation‐inductively coupled plasma‐mass spectrometry analysis reveals differences in chemotherapeutic drug distribution in surgically resected pleural mesothelioma Open
Aims Pleural mesothelioma (PM) is a highly aggressive thoracic tumour with poor prognosis. Although reduced tissue drug accumulation is one of the key features of platinum (Pt) resistance, little is known about Pt distribution in human PM.…
View article: Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Trabectedin synergizes with the bcl-2 inhibitor obatoclax in a pleural mesothelioma cell model
View article: Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Supplementary Table S1: Source, background, histology of the tumor and sensitivity towards trabectedin and cisplatin of all mesothelial and mesothelioma cell models used Supplementary Table S2: Cell death-related genes most differently exp…
View article: Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary video from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Trabectedin synergizes with the bcl-2 inhibitor obatoclax in a pleural mesothelioma cell model
View article: Data from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Data from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Malignant pleural mesothelioma (MPM) is characterized by widespread resistance to systemic therapy. Trabectedin is an antineoplastic agent targeting both the malignant cells and the tumor microenvironment that has been approved for the tre…
View article: Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Supplementary Figure S1: Sensitivity of pleural mesothelioma cell models to trabectedin and impact of the histological origin Supplementary Figure S2: Impact of trabectedin on the migratory potential of pleural mesothelioma cell models Sup…
View article: Data from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Data from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Malignant pleural mesothelioma (MPM) is characterized by widespread resistance to systemic therapy. Trabectedin is an antineoplastic agent targeting both the malignant cells and the tumor microenvironment that has been approved for the tre…
View article: Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary figures S1-S6 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Supplementary Figure S1: Sensitivity of pleural mesothelioma cell models to trabectedin and impact of the histological origin Supplementary Figure S2: Impact of trabectedin on the migratory potential of pleural mesothelioma cell models Sup…
View article: Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i>
Supplementary tables S1-S2 from Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition <i>In Vitro</i> Open
Supplementary Table S1: Source, background, histology of the tumor and sensitivity towards trabectedin and cisplatin of all mesothelial and mesothelioma cell models used Supplementary Table S2: Cell death-related genes most differently exp…
View article: Supplementary Figure S2 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Supplementary Figure S2 from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Supplementary Figure S2. C-reactive protein (CRP) levels of MPM patients and their relation to TERT promoter status in the tumor.
View article: Data from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
Data from Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup Open
Purpose:Human malignant pleural mesothelioma (MPM) is characterized by dismal prognosis. Consequently, dissection of molecular mechanisms driving malignancy is of key importance. Here we investigate whether activating mutations in the telo…
View article: Supplementary Data from Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
Supplementary Data from Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features Open
This file contains Supplementary Material and Methods. Supplementary Table S1 summarizes the antibodies used for IHC and WB; Supplementary Table S2 shows the primers and the shRNAs sequences used; Supplementary Table S3 shows the Selumetin…